Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Polycystic Kidney Diseases

• Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
• A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
• Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
• A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
• HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
• Treatment of Vascular Stiffness in ADPKD
• Open-label, Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
• PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
• Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
• To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects
• A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
• A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
• Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat
• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease
• Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
• Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
• Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
• Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
• A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
• Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
• Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
• Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease
• Effect of Venglustat in Patients With Renal Impairment
• Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
• Tolvaptan-Octreotide LAR Combination in ADPKD
• A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
• The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
• Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
• Statin Therapy in Patients With Early Stage ADPKD
• Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
• A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
• Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
• Feasibility Study of Metformin Therapy in ADPKD
• Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
• Efficacy of Tolvaptan on ADPKD Patients
• Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
• Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
• Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
• Effect of the Aquaretic Tolvaptan on Nitric Oxide System
• Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
• Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
• Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
• The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
• Lanreotide In Polycystic Kidney Disease Study
• Effects of Somatostatin on Liver in ADPKD
• Effects of Somatostatin on ADPKD Heart
• Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease
• Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
• Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control
• HALT Progression of Polycystic Kidney Disease Study B
• Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Sirolimus for Massive Polycystic Liver
• Pasireotide LAR in Severe Polycystic Liver Disease
• The Vienna RAP Pilot Study
• Study of Lanreotide to Treat Polycystic Kidney Disease
• A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
• 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
• Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
• Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
• Bosutinib For Autosomal Dominant Polycystic Kidney Disease
• Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
• Tolvaptan Extension Study in Participants With ADPKD
• Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
• A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
• Everolimus on CKD Progression in ADPKD Patients
• Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
• Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)
• A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
• Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease
• Open-Label Extension of LOCKCYST Trial
• Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
• Lanreotide as Treatment of Polycystic Livers
• CCB Safety Study in Treatment of Hypertension of ADPKD
• Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety
• Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Octreotide in Severe Polycystic Liver Disease
• Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
• Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis
• Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
• Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• HALT Progression of Polycystic Kidney Disease Study A
• HALT Progression of Polycystic Kidney Disease Study B